In a bold move that could reshape the landscape of pharmaceutical pricing, President Donald Trump has issued an executive order demanding that drug manufacturers voluntarily reduce the cost of prescription medications in the United States.
The order, which sets a 30-day deadline, threatens that failure to comply will result in the government imposing new limits on what it will pay for these drugs.
The centerpiece of this initiative is a directive for the Department of Health and Human Services, led by Robert F. Kennedy Jr., to renegotiate drug prices within the next month.
If negotiations falter, Kennedy is tasked with crafting a new rule to align U.S. drug prices with those of other countries, ostensibly to prevent Americans from paying more than their counterparts abroad.
“We’re going to equalize,” Trump declared at a press conference.
“We’re all going to pay the same.”
“We’re going to pay what Europe pays.”
However, the precise impact of this executive order on the millions of Americans with private health insurance remains murky.
The federal government wields significant influence over drug prices through Medicare and Medicaid, which collectively cover nearly 150 million Americans. These programs spend hundreds of billions of dollars annually on medications, and any changes in their pricing policies could have far-reaching implications.
The pharmaceutical industry, unsurprisingly, has been swift and vociferous in its opposition. The Pharmaceutical Research and Manufacturers of America (PhRMA), representing top U.S. drugmakers, has condemned the order as detrimental to American patients.
“Importing foreign prices from socialist countries would be a bad deal for American patients and workers,” stated Stephen J. Ubl, PhRMA’s President and CEO.
He warned that reduced profits could stifle innovation and curtail investment in the development of new treatments and cures.
This executive order is not without precedent.
Trump previously attempted to implement a similar “most favored nation” pricing model during his first term.
That initiative, introduced in the twilight of his presidency, aimed to peg U.S. drug prices to those paid by other countries for certain medications. However, it faced legal challenges and was ultimately shelved under President Joe Biden’s administration.
Despite his historical alignment with pharmaceutical companies, Trump has placed the blame for high drug costs squarely on the shoulders of foreign nations.
At the White House announcement, flanked by influential health officials including Dr. Mehmet Oz and Dr. Marty Makary, Trump threatened pharmaceutical companies with federal investigations into their pricing practices and hinted at opening the U.S. market to more imported medications.
While Trump has touted potential savings in the trillions, the administration has yet to provide concrete figures.
Health officials, including Centers for Medicare and Medicaid Services (CMS) administrator Dr. Oz, are scheduled to engage in negotiations with drug company executives over the next 30 days.
The goal is to propose prices that reflect those paid by other countries.
Skepticism abounds among experts regarding the order’s immediate efficacy.
Rachel Sachs, a health law expert at Washington University, noted that Americans are unlikely to see swift relief from rising drug costs.
“It really does seem the plan is to ask manufacturers to voluntarily lower their prices to some point, which is not known,” Sachs observed.
She added that if manufacturers do not comply, the Department of Health and Human Services could take actions that might only begin to lower drug prices years down the line.
The authority of the health department to enact these changes is primarily limited to Medicare and Medicaid, which can set regulations regarding drug pricing. However, the department’s power is not absolute, as evidenced by the recent 2022 law authorizing Medicare to negotiate drug prices, which will not take effect until 2026.
As the clock ticks on the 30-day deadline, the pharmaceutical industry, policymakers, and the American public are left to ponder the potential outcomes of Trump’s latest foray into drug pricing reform.
Whether this executive order will lead to tangible changes or become another point of contention in the ongoing debate over healthcare costs remains to be seen.
For now, the nation watches as negotiations unfold, hoping for a resolution that balances affordability with innovation.
